Atlas Trials

R-Pharm

57 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch R-Pharm

RecordFirmDate
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI (NCT07543744)R-Pharm2025-04-17
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations (NCT07597668)R-Pharm2025-04-16
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer (NCT07386938)R-Pharm2024-08-09
A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (NCT07435324)R-Pharm2024-08-08
Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter (NCT05773170)R-Pharm2022-11-11
Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 (NCT04684446)R-Pharm2021-09-15
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection (NCT05196477)R-Pharm2021-07-14
Study of Efficacy of Different Treatment Regimens of Olokizumab (NCT05187793)R-Pharm2021-07-08
Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention (NCT04686773)R-Pharm2021-03-05
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). (NCT04452474)R-Pharm2020-06-30
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma (NCT07435311)R-Pharm2020-06-15
Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19 (NCT04501783)R-Pharm2020-05-20
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1 (NCT04246723)R-Pharm2019-05-06
Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin® (NCT03659305)R-Pharm2018-07-10
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack (NCT04067492)R-Pharm2018-03-26
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b (NCT03485846)R-Pharm2017-11-27

Track R-Pharm automatically

Every clearance here is in the API, with alerts when new ones post.